Clinical Trial Update: Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 2 study evaluating Effisayil for flare-ups of generalized pustular psoriasis, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• Effisayil (Spesolimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Generalized Pustular Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2022-03-09